Federal Stem Cell Research: What Taxpayers Should Know

Introduction We are in the midst of a major national debate on stem cell research. There are a variety of ethical and religious views on this issue, and these perspectives are important. But there are also practical and scientific issues. The Heritage Foundation recently hosted a panel discussion to raise and discuss these issues. This paper presents excerpts from the remarks of three speakers at that event. All three have expertise in the subject and regularly address the public policy questions involved in stem cell research. Kelly Hollowell, Ph.D., is a molecular and cellular pharmacologist and a patent attorney. Phil Coelho is CEO and Chairman of the Board of Thermogenesis Corp., which provides cord blood stem cell processing and cryopreservation systems used by major cord blood stem cell banks. And Representative Dave Weldon is a physician and represents the 15th Congressional District of Florida.

--Robert Moffit, Ph.D.

Kelly Hollowell, Ph.D.: Embryonic stem cells are the unspecialized cells that form the basic building blocks for all of the specialized cell types in the body. Researchers hope to treat human diseases by using stem cells taken from embryos. The primary sources for embryonic stem cells are aborted fetuses and the donated and unused embryos housed in in vitro fertilization (IVF) facilities. To obtain embryonic stem cells, an embryo is formed and allowed to mature for five to seven days. The inner mass of the stem cells is then removed, plated, and treated with chemicals to become specialized cell types. In theory, these specialized cells will be used to treat dead, diseased, or dying tissue.

Ethical Issues In the process of harvesting embryonic stem cells, the embryo is destroyed. The primary ethical question raised is whether embryos are People or property. A second ethical issue lies in the extreme inefficiency of harvesting embryonic stem cells. Specifically, the process requires women's eggs. To treat, for example, the 17 million diabetes patients in the United States will require a minimum of 850 million to 1.7 billion human eggs. Collecting 10 eggs per donor will require a minimum of 85 to 170 million women. The total cost would be astronomical, at $100,000 to $200,000 for 50 to 100 human eggs per each patient.

Even more important than the dollars and the difficulty is that the process of harvesting a woman's eggs for stem cells places that woman at risk. Superovulation regimens for fertility treatments would be used to obtain women's eggs. The risks associated with superovulation regimens or high-dose hormone therapies are debated. But there is a growing body of evidence showing that these practices, when used for standard IVF, can cause a wide spectrum of problems including memory loss, seizure, stroke, infertility, cancer, and even death. This points to yet another ethical issue: the future commercial exploitation of women, and particularly poor women, to collect their eggs.

Practical Results No currently approved treatments have been obtained using embryonic stem cells. There are no human trials-despite all the hype and all the media. After 20 years of research, embryonic stem cells haven't been used to treat People because the cells are unproven and unsafe. They tend to produce tumors, cause transplant rejection, and form the wrong kinds of cells.

Private investors aren't funding embryonic stem cell research. They are funding adult stem cell research, which is an ethical alternative. Some of the most startling advancements using adult stem cells have come in treating Parkinson's disease, juvenile diabetes, and spinal cord injuries.

The scientific data on embryonic stem cell research simply does not support continued investment in research. Even if the research were successful, it is morally bankrupt and endangers women. Federal funding should not be used to pay for research that many Americans know is morally wrong and scientifically unsound. That makes embryonic stem cell research a bad investment for our tax dollars.

Philip H. Coelho: Let's take a look at three sources of stem cells: embryonic stem cells, adult bone marrow stem cells, and neo-natal cord blood stem cells. Embryonic stem cells have theoretical advantages: they can become all the different tissues of the body and they have a whole life's worth of cell divisions available to them. But they have also triggered malignant carcinomas in animals, and so researchers are cautious about expecting any clinical trials using embryonic stem cells in the near term.

Adult stem cells are typically drawn from the bone marrow of patients. They also have advantages and have been used clinically about 30,000 times. They do have some disadvantages, however: there are risks to the donor during extraction; there is significant risk of transmission of infectious disease from donor to recipient; and the cells have the potential for fewer divisions.

More here:
Federal Stem Cell Research: What Taxpayers Should Know